Prostate Cancer (Therapy)

Advanced Cancer Drug To Be Introduced

Published in Cancer Weekly, October 7th, 1996

Hoechst Marion Roussel, Kansas City, Missouri, announced that Nilandron (nilutamide) has been cleared by the U.S. Food and Drug Administration (FDA) for marketing in the United States.

Nilandron is an oral, once-daily antiandrogen therapy for men with advanced prostate cancer. Indicated for use in combination with surgical castration (orchiectomy) for the treatment of advanced prostate cancer (cancer that has spread to other parts of the body), Nilandron has been scheduled for launching in the United States in the fall of 1996. For maximum benefit, Nilandron must be started on the same day as or on the day after surgery.

Currently, there is no cure...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1996-10-07)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry